BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11377023)

  • 21. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
    Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
    Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
    Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.
    Yu C; Shin YG; Kosmeder JW; Pezzuto JM; van Breemen RB
    Rapid Commun Mass Spectrom; 2003; 17(4):307-13. PubMed ID: 12569440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.
    Suzuki H; Kneller MB; Haining RL; Trager WF; Rettie AE
    Drug Metab Dispos; 2002 Mar; 30(3):235-9. PubMed ID: 11854139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
    Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
    Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
    Taavitsainen P; Juvonen R; Pelkonen O
    Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19.
    Zhang W; Ramamoorthy Y; Tyndale RF; Glick SD; Maisonneuve IM; Kuehne ME; Sellers EM
    Drug Metab Dispos; 2002 Jun; 30(6):663-9. PubMed ID: 12019193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.
    Desta Z; Soukhova NV; Flockhart DA
    Antimicrob Agents Chemother; 2001 Feb; 45(2):382-92. PubMed ID: 11158730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
    Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
    J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.
    Youdim KA; Lyons R; Payne L; Jones BC; Saunders K
    J Pharm Biomed Anal; 2008 Sep; 48(1):92-9. PubMed ID: 18584988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
    Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
    J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition by ticlopidine and its derivatives of human liver cytochrome p450. Mechanism-based inactivation of CYP 2C19 by ticlopidine.
    Ha-Duong NT; Dijols S; Macherey AC; Dansette PM; Mansuy D
    Adv Exp Med Biol; 2001; 500():145-8. PubMed ID: 11764927
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography.
    Lin T; Pan K; Mordenti J; Pan L
    J Pharm Sci; 2007 Sep; 96(9):2485-93. PubMed ID: 17542019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail.
    Sevior DK; Hokkanen J; Tolonen A; Abass K; Tursas L; Pelkonen O; Ahokas JT
    Xenobiotica; 2010 Apr; 40(4):245-54. PubMed ID: 20218935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breaking the sensitivity limitations of cytochrome P450 oxidation product: dansyl chloride derivatisation of 4-OH mephenytoin, a CYP2C19 metabolite and its application to in vitro CYP inhibition assay.
    Vijayabhaskar V; Srivastava P; Rajagopal S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():27-36. PubMed ID: 25797720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.